Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 10/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9502919 | 0.78 | FDPS (0.40) | FDPSLPAR3LPAR1LPAR2GGPS1 | |
| SCHEMBL8193965 | 0.76 | FDPS (0.39) | FDPSLPAR3LPAR1LPAR2GGPS1 | |
| SCHEMBL3368951 | 0.72 | FDPS (0.40) | FDPSSMPD1LMNA | |
| SCHEMBL9000188 | 0.72 | FDPS (0.32) | FDPSGGPS1 | |
| SCHEMBL9125627 | 0.70 | FDPS (0.34) | FDPSLPAR3LPAR1LPAR2GGPS1 | |
| SCHEMBL9126175 | 0.70 | FDPS (0.38) | FDPSSMPD1LPAR3LPAR1LPAR2 | |
| SCHEMBL8722288 | 0.69 | PPARD (0.35) | FDPSLPAR3LPAR1LPAR2GGPS1 | |
| SCHEMBL10700021 | 0.69 | FDPS (0.33) | FDPSLPAR3LPAR1LPAR2GGPS1 | |
| SCHEMBL10628363 | 0.69 | LAP3 (0.34) | FDPSLPAR3LPAR1LPAR2LAP3 | |
| SCHEMBL18813385 | 0.69 | LPAR3 (0.34) | FDPSLPAR3LPAR1LPAR2GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470724-B2 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | PHOSPHO1, NFATC1, IFNG | FDPS 363/4885SMPD1 827/4885LPAR3 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.